Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of PF-07853578 in Healthy Adults
NCT05890105Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07853578 in metabolic dysfunction-associated steatohepatitis (MASH) (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants Reporting Treatment-Emergent Adverse Events, Number of Participants With Clinical Laboratory Abnormalities and 2 more. Started Jun 2023; status: completed.
02
Drugs
PF-07853578
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT05890105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890105.